…in the TGCA-OV set. To gain insights around treatment resistance, particular attention was paid to homologous recombination-deficient (HRD) disease status, presence of BRCA1 or BRCA2 mutations, and associated response to…
…primary recommendation for women of high risk, specifically after having children, before the age of 40 for BRCA1 carriers, and before 45 years of age for BRCA2 carriers. “Up until…
…in their ability to kill cancer cells. PARP inhibitors are a class of drugs that have shown promising results against ovarian cancer in women with BRCA1 and BRCA2 gene mutations….
…cancers respond to particular treatments or better tolerate treatment at a lower starting dose (predictive biomarkers). Biomarkers can be mutation carrier status (BRCA1 or 2+), molecular characteristics of tumors (HRD,…
…in honor of Rebecca Hafner, who lost her life to ovarian cancer. They partner with breast cancer organizations to hold combined events, raising awareness about the BRCA1 and BRCA2 inherited…
…seen in women who were BRCA1 or BRCA2 positive or women who were premenopausal. 11 on For Some, Statin Use Can Decrease the Risk of Ovarian Cancer The best outcomes…
…including OCRA grantee Ursula Matulonis, MD, treated BRCA-1 deficient tumors with olaparib, a PARPi, and found that it began both a natural and medically induced antitumor process that was STING…
…with cyclophosphamide alone, according to a phase II study evaluating patients with high-grade serous ovarian cancer, peritoneal, fallopian tube, and BRCA-mutant ovarian cancers. The research was reported in Clinical Cancer…
…for Immunology, “Studying the role of BRCA1 in regulating heterochromatin structure and function in ovarian cancer” Bojana Stefanovska, PhD, University of Minnesota – Twin Cities, “APOBEC3B and DNA Repair as…
…to be approved by the FDA that does not require BRCA mutation or other biomarker testing. TESARO anticipates launching niraparib in the United States in late April. READ MORE… 11…
…in improving benefits and reducing harmful outcomes.” The report also calls for genetic counseling for women with increased risk of BRCA mutations. The USPSTF is an independent panel of health…
…population levels. In studying the origin of HGSC, it remains important to separate cases driven by germline mutations in BRCA1/2 or other ovarian cancer susceptibility genes from sporadic carcinomas. Eckert…
Get email updates about research news, action alerts, and ways to join the fight.
